Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Daniele RossiniSara LonardiCarlotta AntoniottiDaniele SantiniGianluca TomaselloPaola ErmacoraMarco Maria GermaniFrancesca BergamoVincenzo RicciSalvatore CaponnettoRoberto MorettoAlberto ZaniboniFilippo PietrantonioAngela BuonadonnaGiuliana RitortoGianluca MasiTiziana Pia LatianoStefania RapisardiAlfredo FalconeChiara CremoliniPublished in: British journal of cancer (2020)
First-line FOLFOXIRI/bev does not impair the administration of effective second-line therapies. First-line response and longer OIFI seem associated with improved response and 2nd PFS from FOLFOXIRI ± bev reintroduction, without impacting 2nd OS.